Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma
To explore the clinical significance of preoperative serum CEA, CA125, and CA19-9 levels in predicting the resectability of cholangiocarcinoma. Patients with cholangiocarcinoma diagnosed by radiologic examination and admitted to the Second Affiliated Hospital of Harbin Medical University from Septem...
Gespeichert in:
| Veröffentlicht in: | Disease markers 2019-01, Vol.2019 (2019), p.1-7 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7 |
|---|---|
| container_issue | 2019 |
| container_start_page | 1 |
| container_title | Disease markers |
| container_volume | 2019 |
| creator | Cui, Yunfu Lin, Xuan Wang, Yufu Wang, Hao Fang, Tianyi Wang, Zhidong |
| description | To explore the clinical significance of preoperative serum CEA, CA125, and CA19-9 levels in predicting the resectability of cholangiocarcinoma. Patients with cholangiocarcinoma diagnosed by radiologic examination and admitted to the Second Affiliated Hospital of Harbin Medical University from September 1, 2011, to November 30, 2017, were retrospectively included. The relationship between the preoperative serum CEA, CA125, and CA19-9 levels and the resectability of cholangiocarcinoma was analyzed by receiver operating characteristic (ROC) curve, as well as the best cut-off point. A total of 112 met the inclusion criteria. In 50 patients with radical surgeries, the levels of preoperative serums CEA, CA125, and CA19-9 were 5.0 ± 13.9 ng/mL, 15.3 ± 11.8 U/mL, and 257.5 ± 325.6 U/mL, respectively, which were lower than those in patients with unresectable tumor. Based on the ROC curve, the ideal CA19-9 cut-off value was determined to be 1064.1 U/mL in prediction of resectability, with a sensitivity of 53.2%, a specificity of 94.0%, and the area under the ROC curve of 0.73 (P |
| doi_str_mv | 10.1155/2019/6016931 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6378785</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2182496297</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-6bf800a58c2b011eb3ebb4b8585bf75b0d1b9e658c50f394d4eddc6067641c713</originalsourceid><addsrcrecordid>eNqNkc1r3DAQxU1paTZpbz0XQS-FrhuNLUvWJbCY9AMWWpr2bCR5vKvglbaSvSWn_uuR2W36ceppBuY3j_d4WfYC6FuAqrosKMhLToHLEh5lC6hFlde8pI-zBS1EndOC0bPsPMZbSqGQTD7NzkqaCMb5IvvZDNZZowZyYzfO9ml1BonvyeeAfo9BjfaA5AbDtCPN9WpJmhUU1ZIo182rzCVZ4wGHSKybfzprRus2ZNwi-YIRzai0Hex4N2s2Wz8ot7HeqGCs8zv1LHvSqyHi89O8yL69u_7afMjXn95_bFbr3DABY851X1OqqtoUmgKgLlFrpuuqrnQvKk070BJ5ule0LyXrGHad4ZQLzsAIKC-yq6PuftI77Ay6Maih3Qe7U-Gu9cq2f1-c3bYbf2h5KWpRV0ng9Ukg-O8TxrHd2WhwSHnQT7EtQEJyVsKMvvoHvfVTcCleouqCSV5IkajlkTLBxxiwfzADtJ2bbedm21OzCX_5Z4AH-FeVCXhzBLbWdeqH_U85TAz26jcNTCSH5T1cVbRA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2182496297</pqid></control><display><type>article</type><title>Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley-Blackwell Open Access Titles</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Cui, Yunfu ; Lin, Xuan ; Wang, Yufu ; Wang, Hao ; Fang, Tianyi ; Wang, Zhidong</creator><contributor>Shi, Zhongjie ; Zhongjie Shi</contributor><creatorcontrib>Cui, Yunfu ; Lin, Xuan ; Wang, Yufu ; Wang, Hao ; Fang, Tianyi ; Wang, Zhidong ; Shi, Zhongjie ; Zhongjie Shi</creatorcontrib><description>To explore the clinical significance of preoperative serum CEA, CA125, and CA19-9 levels in predicting the resectability of cholangiocarcinoma. Patients with cholangiocarcinoma diagnosed by radiologic examination and admitted to the Second Affiliated Hospital of Harbin Medical University from September 1, 2011, to November 30, 2017, were retrospectively included. The relationship between the preoperative serum CEA, CA125, and CA19-9 levels and the resectability of cholangiocarcinoma was analyzed by receiver operating characteristic (ROC) curve, as well as the best cut-off point. A total of 112 met the inclusion criteria. In 50 patients with radical surgeries, the levels of preoperative serums CEA, CA125, and CA19-9 were 5.0 ± 13.9 ng/mL, 15.3 ± 11.8 U/mL, and 257.5 ± 325.6 U/mL, respectively, which were lower than those in patients with unresectable tumor. Based on the ROC curve, the ideal CA19-9 cut-off value was determined to be 1064.1 U/mL in prediction of resectability, with a sensitivity of 53.2%, a specificity of 94.0%, and the area under the ROC curve of 0.73 (P<0.05). The cut-off value of CA125 was 17.8 U/mL with a sensitivity of 72.6%, a specificity of 78.0%, and the area under the ROC curve of 0.81 (P<0.05). The cut-off value of CEA was 2.6 ng/mL with a sensitivity of 79.0%, a specificity of 48.0%, and the area under the ROC curve of 0.66 (P<0.05). In addition to this, we found that using the combination of three tumor markers could improve the value in predicting resectability of cholangiocarcinoma. In summary, this study suggested that the preoperative serum CEA, CA125, and CA19-9 levels can help predict the resectability of cholangiocarcinoma.</description><identifier>ISSN: 0278-0240</identifier><identifier>EISSN: 1875-8630</identifier><identifier>DOI: 10.1155/2019/6016931</identifier><identifier>PMID: 30863466</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Antigens ; Bile ; Biomarkers ; Cholangiocarcinoma ; Clinical significance ; Endoscopy ; Gastroenterology ; Hepatology ; Medical imaging ; Medical prognosis ; Metastasis ; Patients ; Predictions ; Sensitivity ; Serum ; Statistical analysis ; Surgery ; Tumor markers ; Tumors ; Ultrasonic imaging</subject><ispartof>Disease markers, 2019-01, Vol.2019 (2019), p.1-7</ispartof><rights>Copyright © 2019 Tianyi Fang et al.</rights><rights>Copyright © 2019 Tianyi Fang et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. http://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2019 Tianyi Fang et al. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c471t-6bf800a58c2b011eb3ebb4b8585bf75b0d1b9e658c50f394d4eddc6067641c713</citedby><cites>FETCH-LOGICAL-c471t-6bf800a58c2b011eb3ebb4b8585bf75b0d1b9e658c50f394d4eddc6067641c713</cites><orcidid>0000-0001-7393-1680 ; 0000-0003-3325-5758</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378785/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378785/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30863466$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Shi, Zhongjie</contributor><contributor>Zhongjie Shi</contributor><creatorcontrib>Cui, Yunfu</creatorcontrib><creatorcontrib>Lin, Xuan</creatorcontrib><creatorcontrib>Wang, Yufu</creatorcontrib><creatorcontrib>Wang, Hao</creatorcontrib><creatorcontrib>Fang, Tianyi</creatorcontrib><creatorcontrib>Wang, Zhidong</creatorcontrib><title>Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma</title><title>Disease markers</title><addtitle>Dis Markers</addtitle><description>To explore the clinical significance of preoperative serum CEA, CA125, and CA19-9 levels in predicting the resectability of cholangiocarcinoma. Patients with cholangiocarcinoma diagnosed by radiologic examination and admitted to the Second Affiliated Hospital of Harbin Medical University from September 1, 2011, to November 30, 2017, were retrospectively included. The relationship between the preoperative serum CEA, CA125, and CA19-9 levels and the resectability of cholangiocarcinoma was analyzed by receiver operating characteristic (ROC) curve, as well as the best cut-off point. A total of 112 met the inclusion criteria. In 50 patients with radical surgeries, the levels of preoperative serums CEA, CA125, and CA19-9 were 5.0 ± 13.9 ng/mL, 15.3 ± 11.8 U/mL, and 257.5 ± 325.6 U/mL, respectively, which were lower than those in patients with unresectable tumor. Based on the ROC curve, the ideal CA19-9 cut-off value was determined to be 1064.1 U/mL in prediction of resectability, with a sensitivity of 53.2%, a specificity of 94.0%, and the area under the ROC curve of 0.73 (P<0.05). The cut-off value of CA125 was 17.8 U/mL with a sensitivity of 72.6%, a specificity of 78.0%, and the area under the ROC curve of 0.81 (P<0.05). The cut-off value of CEA was 2.6 ng/mL with a sensitivity of 79.0%, a specificity of 48.0%, and the area under the ROC curve of 0.66 (P<0.05). In addition to this, we found that using the combination of three tumor markers could improve the value in predicting resectability of cholangiocarcinoma. In summary, this study suggested that the preoperative serum CEA, CA125, and CA19-9 levels can help predict the resectability of cholangiocarcinoma.</description><subject>Antigens</subject><subject>Bile</subject><subject>Biomarkers</subject><subject>Cholangiocarcinoma</subject><subject>Clinical significance</subject><subject>Endoscopy</subject><subject>Gastroenterology</subject><subject>Hepatology</subject><subject>Medical imaging</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Patients</subject><subject>Predictions</subject><subject>Sensitivity</subject><subject>Serum</subject><subject>Statistical analysis</subject><subject>Surgery</subject><subject>Tumor markers</subject><subject>Tumors</subject><subject>Ultrasonic imaging</subject><issn>0278-0240</issn><issn>1875-8630</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><recordid>eNqNkc1r3DAQxU1paTZpbz0XQS-FrhuNLUvWJbCY9AMWWpr2bCR5vKvglbaSvSWn_uuR2W36ceppBuY3j_d4WfYC6FuAqrosKMhLToHLEh5lC6hFlde8pI-zBS1EndOC0bPsPMZbSqGQTD7NzkqaCMb5IvvZDNZZowZyYzfO9ml1BonvyeeAfo9BjfaA5AbDtCPN9WpJmhUU1ZIo182rzCVZ4wGHSKybfzprRus2ZNwi-YIRzai0Hex4N2s2Wz8ot7HeqGCs8zv1LHvSqyHi89O8yL69u_7afMjXn95_bFbr3DABY851X1OqqtoUmgKgLlFrpuuqrnQvKk070BJ5ule0LyXrGHad4ZQLzsAIKC-yq6PuftI77Ay6Maih3Qe7U-Gu9cq2f1-c3bYbf2h5KWpRV0ng9Ukg-O8TxrHd2WhwSHnQT7EtQEJyVsKMvvoHvfVTcCleouqCSV5IkajlkTLBxxiwfzADtJ2bbedm21OzCX_5Z4AH-FeVCXhzBLbWdeqH_U85TAz26jcNTCSH5T1cVbRA</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Cui, Yunfu</creator><creator>Lin, Xuan</creator><creator>Wang, Yufu</creator><creator>Wang, Hao</creator><creator>Fang, Tianyi</creator><creator>Wang, Zhidong</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7TK</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7393-1680</orcidid><orcidid>https://orcid.org/0000-0003-3325-5758</orcidid></search><sort><creationdate>20190101</creationdate><title>Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma</title><author>Cui, Yunfu ; Lin, Xuan ; Wang, Yufu ; Wang, Hao ; Fang, Tianyi ; Wang, Zhidong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-6bf800a58c2b011eb3ebb4b8585bf75b0d1b9e658c50f394d4eddc6067641c713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antigens</topic><topic>Bile</topic><topic>Biomarkers</topic><topic>Cholangiocarcinoma</topic><topic>Clinical significance</topic><topic>Endoscopy</topic><topic>Gastroenterology</topic><topic>Hepatology</topic><topic>Medical imaging</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Patients</topic><topic>Predictions</topic><topic>Sensitivity</topic><topic>Serum</topic><topic>Statistical analysis</topic><topic>Surgery</topic><topic>Tumor markers</topic><topic>Tumors</topic><topic>Ultrasonic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cui, Yunfu</creatorcontrib><creatorcontrib>Lin, Xuan</creatorcontrib><creatorcontrib>Wang, Yufu</creatorcontrib><creatorcontrib>Wang, Hao</creatorcontrib><creatorcontrib>Fang, Tianyi</creatorcontrib><creatorcontrib>Wang, Zhidong</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Disease markers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cui, Yunfu</au><au>Lin, Xuan</au><au>Wang, Yufu</au><au>Wang, Hao</au><au>Fang, Tianyi</au><au>Wang, Zhidong</au><au>Shi, Zhongjie</au><au>Zhongjie Shi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma</atitle><jtitle>Disease markers</jtitle><addtitle>Dis Markers</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>2019</volume><issue>2019</issue><spage>1</spage><epage>7</epage><pages>1-7</pages><issn>0278-0240</issn><eissn>1875-8630</eissn><abstract>To explore the clinical significance of preoperative serum CEA, CA125, and CA19-9 levels in predicting the resectability of cholangiocarcinoma. Patients with cholangiocarcinoma diagnosed by radiologic examination and admitted to the Second Affiliated Hospital of Harbin Medical University from September 1, 2011, to November 30, 2017, were retrospectively included. The relationship between the preoperative serum CEA, CA125, and CA19-9 levels and the resectability of cholangiocarcinoma was analyzed by receiver operating characteristic (ROC) curve, as well as the best cut-off point. A total of 112 met the inclusion criteria. In 50 patients with radical surgeries, the levels of preoperative serums CEA, CA125, and CA19-9 were 5.0 ± 13.9 ng/mL, 15.3 ± 11.8 U/mL, and 257.5 ± 325.6 U/mL, respectively, which were lower than those in patients with unresectable tumor. Based on the ROC curve, the ideal CA19-9 cut-off value was determined to be 1064.1 U/mL in prediction of resectability, with a sensitivity of 53.2%, a specificity of 94.0%, and the area under the ROC curve of 0.73 (P<0.05). The cut-off value of CA125 was 17.8 U/mL with a sensitivity of 72.6%, a specificity of 78.0%, and the area under the ROC curve of 0.81 (P<0.05). The cut-off value of CEA was 2.6 ng/mL with a sensitivity of 79.0%, a specificity of 48.0%, and the area under the ROC curve of 0.66 (P<0.05). In addition to this, we found that using the combination of three tumor markers could improve the value in predicting resectability of cholangiocarcinoma. In summary, this study suggested that the preoperative serum CEA, CA125, and CA19-9 levels can help predict the resectability of cholangiocarcinoma.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>30863466</pmid><doi>10.1155/2019/6016931</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-7393-1680</orcidid><orcidid>https://orcid.org/0000-0003-3325-5758</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-0240 |
| ispartof | Disease markers, 2019-01, Vol.2019 (2019), p.1-7 |
| issn | 0278-0240 1875-8630 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6378785 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley-Blackwell Open Access Titles; PubMed Central; Alma/SFX Local Collection |
| subjects | Antigens Bile Biomarkers Cholangiocarcinoma Clinical significance Endoscopy Gastroenterology Hepatology Medical imaging Medical prognosis Metastasis Patients Predictions Sensitivity Serum Statistical analysis Surgery Tumor markers Tumors Ultrasonic imaging |
| title | Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T14%3A12%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Significance%20of%20Preoperative%20Serum%20CEA,%20CA125,%20and%20CA19-9%20Levels%20in%20Predicting%20the%20Resectability%20of%20Cholangiocarcinoma&rft.jtitle=Disease%20markers&rft.au=Cui,%20Yunfu&rft.date=2019-01-01&rft.volume=2019&rft.issue=2019&rft.spage=1&rft.epage=7&rft.pages=1-7&rft.issn=0278-0240&rft.eissn=1875-8630&rft_id=info:doi/10.1155/2019/6016931&rft_dat=%3Cproquest_pubme%3E2182496297%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2182496297&rft_id=info:pmid/30863466&rfr_iscdi=true |